Glaukos Corp (GKOS) - Net Assets
Based on the latest financial reports, Glaukos Corp (GKOS) has net assets worth $769.54 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($999.38 Million) and total liabilities ($229.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Glaukos Corp asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $769.54 Million |
| % of Total Assets | 77.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | 14.9% |
| 10-Year Change | 705.68% |
| Growth Volatility | 89.67 |
Glaukos Corp - Net Assets Trend (2012–2024)
This chart illustrates how Glaukos Corp's net assets have evolved over time, based on quarterly financial data. Also explore GKOS asset base for the complete picture of this company's asset base.
Annual Net Assets for Glaukos Corp (2012–2024)
The table below shows the annual net assets of Glaukos Corp from 2012 to 2024. For live valuation and market cap data, see GKOS market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $766.93 Million | +66.09% |
| 2023-12-31 | $461.77 Million | -12.88% |
| 2022-12-31 | $530.00 Million | -9.73% |
| 2021-12-31 | $587.15 Million | -12.03% |
| 2020-12-31 | $667.45 Million | -0.86% |
| 2019-12-31 | $673.27 Million | +287.25% |
| 2018-12-31 | $173.86 Million | +25.80% |
| 2017-12-31 | $138.20 Million | +17.85% |
| 2016-12-31 | $117.27 Million | +23.20% |
| 2015-12-31 | $95.19 Million | +159.16% |
| 2014-12-31 | $-160.90 Million | -7.96% |
| 2013-12-31 | $-149.04 Million | -1564.72% |
| 2012-12-31 | $-8.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Glaukos Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 61083200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $56.00K | 0.01% |
| Other Comprehensive Income | $2.62 Million | 0.34% |
| Other Components | $1.51 Billion | 196.85% |
| Total Equity | $766.93 Million | 100.00% |
Glaukos Corp Competitors by Market Cap
The table below lists competitors of Glaukos Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
QUBE Holdings Ltd
AU:QUB
|
$6.26 Billion |
|
Tianshui Huatian Technology Co Ltd
SHE:002185
|
$6.27 Billion |
|
Elis SA
PA:ELIS
|
$6.27 Billion |
|
SDIC Essence Holdings Co Ltd
SHG:600061
|
$6.28 Billion |
|
Rayonier Inc
NYSE:RYN
|
$6.26 Billion |
|
Ningbo Orient Wires and Cables Co Ltd
SHG:603606
|
$6.25 Billion |
|
ISS A/S
CO:ISS
|
$6.25 Billion |
|
Pegasystems Inc
NASDAQ:PEGA
|
$6.25 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Glaukos Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 461,766,000 to 766,931,000, a change of 305,165,000 (66.1%).
- Net loss of 146,372,000 reduced equity.
- Share repurchases of 6,563,000 reduced equity.
- Other comprehensive income increased equity by 1,450,000.
- Other factors increased equity by 456,650,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-146.37 Million | -19.09% |
| Share Repurchases | $6.56 Million | -0.86% |
| Other Comprehensive Income | $1.45 Million | +0.19% |
| Other Changes | $456.65 Million | +59.54% |
| Total Change | $- | 66.09% |
Book Value vs Market Value Analysis
This analysis compares Glaukos Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.18x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-1.45 | $133.42 | x |
| 2013-12-31 | $-5.68 | $133.42 | x |
| 2014-12-31 | $-6.08 | $133.42 | x |
| 2015-12-31 | $5.45 | $133.42 | x |
| 2016-12-31 | $3.22 | $133.42 | x |
| 2017-12-31 | $4.02 | $133.42 | x |
| 2018-12-31 | $4.92 | $133.42 | x |
| 2019-12-31 | $16.36 | $133.42 | x |
| 2020-12-31 | $15.00 | $133.42 | x |
| 2021-12-31 | $12.65 | $133.42 | x |
| 2022-12-31 | $11.17 | $133.42 | x |
| 2023-12-31 | $9.53 | $133.42 | x |
| 2024-12-31 | $14.54 | $133.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Glaukos Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -38.17%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.27x
- Recent ROE (-19.09%) is below the historical average (-10.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -795.84% | 0.47x | 0.00x | $-19.04 Million |
| 2013 | 0.00% | -60.34% | 0.68x | 0.00x | $1.49 Million |
| 2014 | 0.00% | -26.60% | 1.75x | 0.00x | $3.00 Million |
| 2015 | -39.12% | -51.94% | 0.61x | 1.23x | $-46.76 Million |
| 2016 | 3.86% | 3.95% | 0.85x | 1.15x | $-7.21 Million |
| 2017 | -0.07% | -0.06% | 0.96x | 1.20x | $-13.91 Million |
| 2018 | -7.45% | -7.14% | 0.88x | 1.19x | $-30.34 Million |
| 2019 | 2.29% | 6.51% | 0.29x | 1.22x | $-51.90 Million |
| 2020 | -18.03% | -53.50% | 0.22x | 1.51x | $-187.09 Million |
| 2021 | -8.45% | -16.87% | 0.26x | 1.92x | $-108.31 Million |
| 2022 | -18.72% | -35.07% | 0.26x | 2.03x | $-152.20 Million |
| 2023 | -29.16% | -42.79% | 0.33x | 2.04x | $-180.84 Million |
| 2024 | -19.09% | -38.17% | 0.39x | 1.27x | $-223.07 Million |
Industry Comparison
This section compares Glaukos Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $385,987,292
- Average return on equity (ROE) among peers: -142.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Glaukos Corp (GKOS) | $769.54 Million | 0.00% | 0.30x | $6.26 Billion |
| Abbott Laboratories (ABT) | $3.35 Billion | 37.01% | 1.07x | $151.58 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $20.76 Million |
| Aethlon Medical Inc (AEMD) | $2.30 Million | -269.46% | 0.79x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $4.29 Million | -149.07% | 0.49x | $15.42 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.44 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $1.96 Million | -680.21% | 0.05x | $4.32 Million |
| Artivion Inc (AORT) | $279.04 Million | 1.33% | 1.12x | $1.72 Billion |
| Apyx Medical Inc (APYX) | $6.01 Million | -36.31% | 0.22x | $114.47 Million |
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathw… Read more